| Ticker: EPMD | 58 Route 46 West | |
| Exchange: NASDAQ-National Market | Budd Lake, New Jersey 07828 | |
| Industry: Wholesale | (201) 691-6400 |
| Type of Shares: | Common Shares | Filing Date: | 4/18/96 | |
| U.S. Shares: | 2,500,000 | Offer Date: | 6/21/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $6.00 - $8.00 | |
| Primary Shares: | 2,500,000 | Offer Price: | $5.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.38 | |
| Offering Amount: | $17,500,000 | Selling: | $0.23 | |
| Expenses: | $900,000 | Reallowance: | $0.10 | |
| Shares Out After: | 7,599,917 |
| Manager | Tier | Phone |
| Pacific Growth Equities | Lead Manager | (415) 398-4563 |
| Auditor: Arthur Andersen | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $2.00 | $0.76 | $0.46 | Assets: | $2.49 |
| Net Income: | -$1.48 | -$0.17 | -$0.17 | Liabilities: | $2.34 |
| EPS: | -$0.26 | -$0.03 | -$0.03 | Equity: | $0.15 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company is a leader in the development of a new product for internal cardioversion of atrial fibrillation and also develops, markets, sells and services cardiac electrophysiology products used to diagnose, monitor and treat certain cardiac disorders. The company has developed the Atrial Low Energy Reversion Therapy catheter system, which uses a proprietary electrode catheter to deliver measured, variable, low energy electrical impulses directly to the inside of the heart in order to convert electrical impulses directly to the inside of the heart in order to convert atrial fibrillation to a normal heart rhythm. The company is not aware of any atrial fibrillation to a normal hearth rhythm. The company is not aware of any other product currently begin developed or marketed that permits low energy internal cardioversion of atrial fibrillation with a single catheter. Atrial fibrillation is most commonly found in the elderly. As the elderly segment of the population grows, the atrial fibrillation patient population is also expected to increase. |
| Use of Proceeds |
| The proceeds from the offering will be used for clinical trials and related development, expansion of sales and marketing, expansion of manufacturing and assembly, repayment of debt, and for working capital and general corporate purposes, including potential acquisitions of products and technology. |
©1996 IPO Data Systems, Inc. - All rights reserved.